Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4800 Intradermal Booster with/without INO-9112
NCT05430958Phase 1Withdrawn
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 1, open-label trial of INO-4800 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Percentage of Participants with Solicited Local and Systemic Adverse Events at Day 7, Percentage of Participants with Adverse Events at Day 28 and 4 more. Planned start Oct 2022; status: withdrawn.
02
Drugs
INO-4800
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05430958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430958.